Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-01-02 00:00:00 ET · period of report 2025-12-31 · accession 0001628280-26-000209 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-02 | 2025-12-31 | ARQT | Burnett Patrick | See Remarks | S - Sale | $29.21 | -1,697 | 97.8K | -2% | -$49.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | S | D | 1,156 | $29.39 | 96,610 | D | — | — | (F1) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020. (F3) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $29.0829 to $29.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-12-31 | S | D | 541 | $28.81 | 97,766 | D | — | — | (F1) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.08 to $29.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |